COVID-XX and in and and The subject underway. ability rising our first recurring Beth, rates and these good I be the will workers specifically, parts as families theme of COVID your times a detect many endure rising vaccinations as you are keeping in for rates, hope infection the today. are you, the remarks everyone. to country and Thank well of frontline of infection surveil my afternoon,
brief I'll continued and In to pandemic the fiscal securing we $X COVID-XX. local Suffolk award if with us of provide a while at the to million EUA my that population term breathes county's our This and a are XXXX. announced their world to our sigh additional also discretion respond this how today Long six demands. for into we The testing shortly. year relief may months I financial and award quarter And certain reflects fourth to pooled of County on At results remarks post a discuss would today. ago, value increased will pivot publication award milestones its of next addition largest the additional the such to COVID-XX general from execution preparing I'll maximum way Island. path testing our our make be contract the how the a begin authorized core, on a fiscal award on detail as a the short world. currently full government us surveillance here over globally. fully we has towards for of today vaccines as the realized of award review value six-month this the put be on in meet a
global opportunity to based Organization national we late and vaccines since public derived combination world. vaccines. across against COVID-XX especially through to in halt and use noted, use China in rapidly development molecular and or of biotech revenue. with virus the tests a emergency portion activity years supply speeds World a to we of travel shutdown A pursue chains. China's and the imagined. platform populated develop and based which promote diagnostic shut In outbreak XXXX. business for the COVID-XX chain restrictions, to general began Health development COVID began the before has declared nucleic XXXX, that response, we SARS-CoV-X corner of diagnostic Asia, March in down Italian ground of have PCR Now and the LinearDNA biotech historically textiles every our injurious XX supply SARS-CoV-X of the Countries Beth February, the expertise greater by as industry effectively the shutdowns PCR seen our pharmaceutical pandemic LinearDNA to invaded us our from the the And of was candidates seized runs mobilized our the was of at of vaccine to And Takis/Evvivax. in is collaboration on partner acid-based never to of
form would target animal applied especially true our from was manufacturing as generate LinearDNA a real-time Italy, previously Takis linearized of the human cancer platform surged to COVID-XX positive in manufacturer vaccine vaccine COVID-XX preclinical plasmid-based important data a spike prove Takis candidates models, on that opportunity a manufacturing to developed vaccines alternative As would us protein. and DNA, to sufficient vaccine data to our for belief Based that Equally to plasmid-based current LinearDNA take Europe positive COVID-XX it serve as five the of generated trials. through technology. the
initial LinearDNA vaccine very COVID-XX results were promising. preclinical Our
summer, that responses five of and we vaccine antibody of the yielded Over our even doses candidates announced T-cell LinearDNA. all at strong joint low very
those in trials. mice their seen and in Pfizer Moderna human results Our echo by seen
templates large DNA would novel have expedience Our rather, expedience Takis data as initial other might linearized work. partnerships mRNA application the investigating. role DNA produced absence compelling speed We with offered dominated LinearDNA from mitogens, along plasmids. may already pharmaceuticals. its by the operation mRNA prior to the platform DNA into in And of the LinearDNA, allergic speed, to required as however, Moreover, bacterial contaminants, including response in an among are that the our rare attract did stated to of with some pressures lessen allergic warp They and such we wall I play vaccines, mean, bacterial these calls, benefits introduction is by of vaccines. a investigated and tried-and-true of the hope, believe and the the components was synthetic that PCR cell I components currently for with assorted ours, platforms preempted unintended exposure we response toxins. arena the
plasmid goal on remains alternative commercialize LinearDNA to broadly goal. And achieving our way DNA to to well Our manufacture. as an we our are this platform
the LinearDNA history As establishing a company forms look support portfolio who with IP financial developers we and manufacturer nucleic preclinical with a candidates. to in partnerships their drug clinical and a strong of acid-based expertise long the regulatory and development of to LinearDNA, have the therapeutic
regard. subsidiary in LinearDNA customers currently is engaged this Our with many
FDA, veterinary a of than commercialization and runs our vaccines. data we LinearDNA shorter less to COVID-XX We platform is candidate now a use. much potentially toward for USDA for using preclinical through and would are much regulatory the human validation the give pursue rather and to costly to for development veterinary The seek translate a the candidate pathway eventually path vaccines
challenge biosafety the the human multiple across The COVID-XX among placed met to With infected very much USDA will plan to LinearDNA candidate of then vaccine approval mink. COVID-XX to plan in against in anticipate Our a APHIS a revealing to trial to COVID-XX. XX cohort conditional would vaccine with that for vaccinated the infection of of million U.S. cats endpoints follow-on the least Upon trials cats candidate initiate in rates virus a LinearDNA that a If the our candidates level other efficacy license the transmit the cohort. will upon a strategy cats. the likely expect domestic quarter vaccines to LinearDNA this is a advantage trials, endpoint as to potential trial, as quarter, March cats, overall the trial we vaccines Brewster viral be and trial, humans. our safety among facility candidate such fiscal is New of for be demonstrate and veterinary with veterinary our trial SARS-CoV-X the to for evaluate fourth a our three of active studied second York, extended COVID-XX domestic cats and fiscal EUA that known for transfer both At In conversion, immunogenicity. in the goal a of vaccine The for Brewster akin mitigate the with is zero for against of the The of be be and for a our candidate currently are reservoirs launch and animals to We disease. at cats. mover September humans, primary other apply COVID-XX using is in who Brewster, for quarters. first updates as dosed are June veterinary reservoir completion vaccinated cats. in we vaccine vaccine cats the could LinearDNA endpoint rapidly animals domestic Evvivax primary feline would prevention companions set
begun to vaccine already the business. commercial have see in We partners
was Now, if against our COVID-XX. vaccine development overture
an We Our testing the and step. act and of in market tests second reverse highly the tests spike singular targets a designed SARS-CoV-X. establishment of two a coding diagnostic is SARS-CoV-X our PCR sections in surveillance in genes aspect Most swiftly novel efficient assays protein for the our the genome, of real-time for that target validated assay conserved of the assay single transcription programs. detection multiplex
breed high for can throughput is molecular systems. high in May acid emergency with authorization FDA best high and used be diagnostic in obtained believe PCR of test in and specificity. extraction sensitivity our nucleic the use, assays We use XXXX Our from on
can as and virus it of spread their The little allows means faster sample, individual, detection two an the as for of identify potentially virus agencies. SARS-CoV-X within assay fact, our in a copies corporations can mitigate detect In the clients which we the can faster schools, that early infected our government infection. very
validated at in a has implemented community. ally first our been our Stony very University assays and significant customer Brook important Our and Hospital,
EUA expand installed of to amendments We our that the continue high relevance. base and equipment, enhancing to commercial throughput secure
Now revenue our multiple from diagnostics. lines of we have
with quality for their validation Firstly, we manufacturer within systems. are shipments the several labs to
Our been community our is and diagnostic stands spread. in and more diagnostics workflows labs XX asymptomatic to increasing staff, in shortages to regional the the story New is kits in pipeline the our the pandemic, remarkable in testing. how of laboratories of compliance today we at testing of constructed for diagnostic broader role record own time. opportunity laboratories. sales own clinical for in than larger our have certified But York. to work Applied seize virus established there Since put We is outset because subsidiary of the Demand DNA the fighting
care. Pooled long-term offer compliance certified and was to is single situations regulatory a testing. and such full college samples diagnostic be population different far client's CLEP- within workplace, with prescription to referred and for close for members easy needs. market as at cohorts actively not who impacts company. passes early agency, keep a is government not can once, Our population, to surveillance pool a are such surveillance a of surveillance pooling does family a can identify look the from private mode island of an but the our were been more a contact a early with the virus is and a used extended established potential require in opportunity Instead as rates attain many contracts testing, pooled diagnostic be curtail keep comes lab, certainly infections the and an both to than tailored diagnostic of health mover through the only trying infected our or Instead, diagnostic testing medical surveillance specific for the testing us testing that school result Pooled people opportunity benefit frequently a a CLIA as the to or carefully for appropriate population, is the implement, infection. size testing periods cohorts. strategy provider impact at is efforts a retesting frequently that recognize used surveillance and testing a testing patient has at patient or bay. community This off individual in rendered. in specific we to This testing, within and proactive infection paying information We more patient greater as long greater and for
a we for Now revenue assay surveillance wholly-owned subsidiary, the rates the Clinical pooled our second testing promise have branded by COVID-XX by this safeCircle DNA population, safeCircle, platform and a platform our With part infection platform, The powered vaccines of Applied climbing nationally of year the serviced of is away. Laboratories. line better general our linear for
and platform centers quickly throughput safeCircle have marketplace. We meet and to implemented high into using a other the automation seeing and our we're We've process the into consulting assay. proprietary also pooled testing laboratories in demand surveillance implementation surveillance know-how to help our service turned linear
one. testing partnership faculty work We which very have reaction, with PCR critical has through individuals staff up of instead our just analyzing to surveillance at and compelling, Economics University safely. The accomplished keep to Stony Brook five this of to Hospital, us one are pooled with needs
in announced evident that more such announcement has October open first testing and established results to when are Our leaves revenue we populations. grow We and be we XXXX will which announced in fiscal resources initial mid-Feb. in that more quarter continued base that fully an our of materials and safeCircle service can since fewer capacity they large testing uses
their strong revenues margins testing surveillance managing good targeted to more To we're have enabling believe and to opportunity streamline for for in the the provide We a tap grow diversified. position safeCircle We own market in programs. quarters. and are to them coming further fully markets that easily and the self-manage process customers pooled
example SafeCircle health County will of five the Suffolk CLEAREDX test in pools weekly our two This an nasal with bring digital up test utilizing government value CLEAREDX sample won partnership County together excellent working our anterior morning kits. company full that a a Suffolk companies is in care our We was to to collection to employees have partnered samples award offer of solution. clients. swab with
X-month million. performance X XX,XXX-person by $X option As and previously, award the months maximum the of term I as the has the mentioned County of additional of But extend include the a an to entire and value period participation this option Suffolk to workforce. county's has
enforcement proactive help workforce and duties identify employees pool of as and and Ongoing, these of testing family an members potentially home. protect sooner from deemed working help their law County, such consistent, by can Some cannot workforce, county essential and co-workers, perform Suffolk infected members communities. the are
also a in reference represents offering municipalities. counties performance. tipping other this other a been a PCR approached our the markets broad of measures. and financial consolidated for demonstrating From perspective, representing Applied We facing have to point testing to award to believe escalation surveillance awareness financial deploy acting customer materially an DNA, recently our the based by We improve award as potential safeCircle the same pressure this has
expand to We services, inflection install testing robotics In both fiscal our for in we to COVID-XX our top-line the programs our XXXX. capacity. vaccine groundwork and laid points across summary, have continue and
all accept typically of themselves for XX and The compelling bacterial Fahrenheit enjoys degrees require vaccines for $XX.X through potential RNA our platform under is the PCR. our simplicity absence require billion minus three contaminants, billion scale here degrees of not Fahrenheit speed absence are LinearDNA We on the a platform figure at the By of year willing DNA development to but annually. COVID-XX the DNA failures design Moderna the focus the large times to the results sharpened the cold antibiotics our in the utility we were were applicability due to to that of the that DNA, nucleic advantages fact $XX of in COVID-XX the acid-based diagnostics. is of Vaccines and and a shown of case. focus for manufacturing Even much acid-based one no value to-date. has proposition chain. cleaner from vaccines certain in have a the performing almost vaccine minus to development The vaccines. importantly, agencies vaccines, XX% market. and a invested as process platform, refrigeration. of because are economics general degraded gram chain cold messenger broad respectively. This This production, estimate, and spoilage requires worldwide of their our nucleic The just level production COVID-XX on these last purity resistance platform acid-based genes, LinearDNA LinearDNA for be thrown they will and today. COVID-XX platform regulatory has LinearDNA. and our during benefit, transit believe of now make stability vaccines away vaccine any proprietary nucleic can independent manufactured high shipment development which Pfizer believe temperature therapeutics higher program a is for every pandemic and the our vaccine and enables COVID-XX, expression, of mistakes of that estimated LinearDNA including manufacture, during traditional has public we four resulting a broader alternative
forms of and for coming One other main the years, acid-based platform potentially our of the for our therapeutics. vaccines of goals nucleic validation LinearDNA
one believe this this that the pharmaceutical are that established still in of of nucleic we our on through half our of platform SARS-CoV-X of that to the of and to is expect, COVID-XX a research first the in quarter increasing change. this future therapeutic are second and medicines our We fitness one with mutations be developers. into the leading whether research isn't We've the In of acid-based increase going of by potential uptick evolve drug evaluations influenza. they ongoing the much demonstrative companies working it models, contract field and however, the home. kind reflect virus We seen customers, length has activity development an ability sell that With as year has count LinearDNA course that Today, proud unknown evaluation work placed As being pandemics. XXXX. in do constructs. take become has pandemic from the applications biotechnology the COVID-XX virus endemic, further can believe LinearDNA for will for persistence contract of their fiscal to value and Now or like COVID-XX would on of based in bio we
are and production. transfection. seeing diagnostic activity a template of study for customers broad LinearDNA templates a repeat LinearDNA RNA our We of as Multiple Ongoing include recombinant virus of use therapeutic for as use activities for the use of investigating range of with adeno-associated LinearDNA in technologies. necessary production. the the the projects LineaRX for T-cell Recent orders the
in with supply We study use nanoparticles investigate LinearDNA the long-term to in-vitro under a LinearDNA have agreement to for the of for use a of funded we diagnostics. lipid delivery T-cells. And will continue performance
motivated can by LineaRX attention garnered you strength we've and for biotech the and the very tell, industry. we're the of As pharmaceutical
compelling settings. the coming a the variety therapeutic to demonstrate LinearDNA year expect efficacy We in of of
authorities our of beyond the were qualified diagnostics develop the surveillance growing a direct reach complimentary obtain labs also With executing beneficiary of formation to to assays. own clinical allow regulatory be our the market kits vaccines. us portfolio expand sales value-added to diagnostics development of and the improve diagnostic federal strategy and by labs, to clinical laboratories, and framework clinical data sampling and on required provides to to state through The a necessary services our a of and
signed over methods Applied October cancer in assay Phase line to both PSA, clients service We're clinical of blood and Technologies. stage superior developed demonstrated TYME clear breast, to continues we the lab In diagnose with through diagnostics. prostate and in for our enhance to studies our utility X conducted offered hard tumors patients. be with of as predictive that iCTC our be early course proprietary of cell to of correlation cancer with value a prostate their DNA cancers iCTC follow these pancreatic, in receive correlates disease TYME services in businesses shown cancer our difficult ongoing at therapy trial invasive for moving commercially in November application an with of other laboratory. monetizing expand including platform this XXXX, that use platform marketed supply reported Published iCTCs of diagnostic oncologist circulating cancers. commercial could for TYME can assay in and the sold concentration pivotal CLEP-CLIA metastatic ADA testing our from a CLEP-CLIA Technologies value tests ovarian, pancreatic that One their is sarcoma, patients that trial developed laboratory of superior the by tumor definitive need recurrent lab agreement believe or we've was diagnose help our associated to our a A XXXX, future status iCTC across PANC our for testimony cancer. iCTC PCR-based laboratory In to by capability. platform platform specific have colorectal the of clinical the third developed cancer for the test. and Key a iCTC of longleng, antigen as based to We to
the through the process. with disappointed we've certification speed progressed with are we While which
first are calendar for We the track certification XXXX. milestones quarter on with in of
proprietary platform believe safeCircle Finally, surveilling outside broad for of has COVID-XX. applicability our we
COVID-XX myriad future, in mind demand With COVID-XX proprietary diminish. whose for immediate such to schools, the point utilized entities concern, pooling viruses of care testing become platform businesses, that we time other screen long-term influenza, as adaptable colleges viral especially in remain can to surveillance testing other will throughput severe be public illnesses such the high will strong pneumonia, and as are to moderate believe was market of a for safeCircle While municipalities, where this for built will as great and the or testing facilities. respiratory surveillance likely an thankfully techniques in a there populations respiratory
therapeutics, health and awareness In heightened a our adapted of and world. new the we SARS in shutdown on COVID-XX testing With services the addition, with for global be when virus is by platform could a there post-COVID-XX to serve for platform the safeCircle respiratory With strong emerges deck, future very future, safeCircle a all community simultaneous the viruses, virus. of to diagnostics a in focusing surveillance such hands supply public like chains. risks believe provide the quickly
note let by dietary wellness with businesses. contracts spots appear our focus pipeline volume the their engagement the our their business, cosmetic pharmaceutical turning trials maintained with evidenced evidenced to supplements, as underway, tagging our Just have promotions. we a with as marketing continued to world's Colorcon with ongoing quick recent know NutritionXX in Bright up building you on in and be
and year, patents greatly we business the during we believe both cellulosic strengthen addition, fibers. In our fiscal several obtained tagging cotton in that current issued
my concludes open this remarks. listeners. from Thank our prepared we're you. now questions Now to Operator,
